Limited Offer
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Antifungal Host Defenses
Translational Implications and Therapeutic Opportunities
- 1st Edition - May 1, 2025
- Editor: Paschalis Vergidis
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 2 3 6 3 6 - 5
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 3 6 3 5 - 8
Antifungal Host Defenses: Translational Implications and Therapeutic Opportunities summarizes the current knowledge on interactions between host cells and human fungal pathogens… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteAntifungal Host Defenses: Translational Implications and Therapeutic Opportunities summarizes the current knowledge on interactions between host cells and human fungal pathogens and explains how certain immune defects lead to vulnerability to fungal infection.
Chapters focus on immune response to such fungal infections as candidiasis, aspergillus, cryptococcosis, mucormycosis, pneumocystis.This title provides a basis for further study on antifungal immunity by enhancing understanding of antifungal immune responses. Further, this title offers new insights from the host immune response, improving understanding of disease pathogenesis and informing novel prophylactic and therapeutic approaches to fungal infections.
- Covers complex immune responses against superficial and systemic mycoses
- Identifies key mechanisms by which immune defects predispose to fungal infection
- Offers potential applications of immunotherapy in clinical practices
Basic science researchers in immunology, translational researchers in Medical Mycology, Practicing Infectious Disease Specialists
1. Antifungal Host Defenses and the Risk of Invasive Fungal Infection
2. The IL-17 Pathway and Mucosal Candidiasis
3. The Importance of Spleen Tyrosine Kinase (Syk) in the Immune Response to Candidiasis
4. Dectin-1, Interferon Expression and the Host Immune Response Against Aspergillus fumigatus
5. The Role of Pentraxin-3 in Invasive Aspergillosis
6. Breaches in Antifungal Immunity and Viral-Associated Aspergillosis
7. CARD-9-Dependent Neutrophil Recruitment and Fungal Infection
8. Dendritic Cell Responses to Cryptococcal Infection
9. Development of Glucan Particle-Based Vaccines for Cryptococcosis
10. Tissue Invasion in Mucormycosis and the Role of Coat Protein Homologs
11. TNF-alpha Antagonists and Susceptibility to Histoplasmosis
12. Genetic Predisposition to Disseminated Coccidioidomycosis
13. Anti-CD20 Therapy and Risk of Pneumocystis Pneumonia
14. Bruton Tyrosine Kinase Inhibitors and Risk of Fungal Infection
15. Bioengineering T-cells to Treat Invasive Aspergillus Infection
2. The IL-17 Pathway and Mucosal Candidiasis
3. The Importance of Spleen Tyrosine Kinase (Syk) in the Immune Response to Candidiasis
4. Dectin-1, Interferon Expression and the Host Immune Response Against Aspergillus fumigatus
5. The Role of Pentraxin-3 in Invasive Aspergillosis
6. Breaches in Antifungal Immunity and Viral-Associated Aspergillosis
7. CARD-9-Dependent Neutrophil Recruitment and Fungal Infection
8. Dendritic Cell Responses to Cryptococcal Infection
9. Development of Glucan Particle-Based Vaccines for Cryptococcosis
10. Tissue Invasion in Mucormycosis and the Role of Coat Protein Homologs
11. TNF-alpha Antagonists and Susceptibility to Histoplasmosis
12. Genetic Predisposition to Disseminated Coccidioidomycosis
13. Anti-CD20 Therapy and Risk of Pneumocystis Pneumonia
14. Bruton Tyrosine Kinase Inhibitors and Risk of Fungal Infection
15. Bioengineering T-cells to Treat Invasive Aspergillus Infection
- No. of pages: 200
- Language: English
- Edition: 1
- Published: May 1, 2025
- Imprint: Academic Press
- Paperback ISBN: 9780443236365
- eBook ISBN: 9780443236358
PV
Paschalis Vergidis
Paschalis Vergidis, MD, MSc, FECMM, is an Infectious Disease specialist with expertise in infections in the immunocompromised host. He trained in Infectious Diseases at Boston University Medical Center and Transplant Infectious Diseases at Mayo Clinic. In 2012, Dr. Vergidis joined the Transplant Infectious Disease Team at the University of Pittsburgh. In 2016, he relocated to the UK to join the National Aspergillosis Center at the University of Manchester then returned to Mayo Clinic in 2019. He is the Focus Group Chair of the Hematology-Oncology Infectious Disease Service, has directed the COVID-19 Service, and is the Ambulatory Antimicrobial Stewardship lead and Antimicrobial Stewardship Education chair. Dr. Vergidis is the site principal investigator for clinical trials on novel antifungal medications and serves as editor for Microbiology Spectrum. In recognition of his expertise in Medical Mycology, he has been accepted as Fellow of the European Confederation of Medical Mycology.
Affiliations and expertise
Associate Professor of Medicine, Division of Public Health, Infectious Diseases & Occupational Medicine, Mayo Clinic, MN, USA